Proteinuria and hypertension with tyrosine kinase inhibitors

Kidney International

Volumn 80, Issue 12, 2011, Pages 1271-1277

  Kandula, Praveen ^a   Agarwal, Rajiv ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

bevacizumab; hypertension; proteinuria; tyrosine kinase inhibitors

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; CD2 ASSOCIATED PROTEIN; CEDIRANIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NEPHRIN; PAZOPANIB; PLACEBO; PODOCIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT VASCULOTROPIN; SORAFENIB; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADVANCED CANCER; ANGIOGENESIS; AWARENESS; DIABETIC NEPHROPATHY; DIGESTIVE SYSTEM PERFORATION; DIMERIZATION; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EVIDENCE BASED MEDICINE; FANCONI RENOTUBULAR SYNDROME; FOCAL GLOMERULOSCLEROSIS; GENE OVEREXPRESSION; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HETEROZYGOSITY; HIDRADENOMA; HOMOZYGOSITY; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; INCIDENCE; KIDNEY BIOPSY; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY TUBULE ACIDOSIS; LEIOMYOSARCOMA; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG ALVEOLUS CELL CARCINOMA; LUNG SMALL CELL CANCER; NEPHROTIC SYNDROME; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PATHOPHYSIOLOGY; PODOCYTE; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEINURIA; PULSE WAVE; QUALITY OF LIFE; REVIEW; STABLE ANGINA PECTORIS; THROMBOEMBOLISM; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; WOUND HEALING IMPAIRMENT;

EID: 82455210240     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.288     Document Type: Short Survey

References (34)

1. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353: 172-187.
2. Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 2010; 60: 222-243.
3. Kawachi H, Suzuki K, Miyauchi N et al. Slit diaphragm dysfunction in proteinuric states: identification of novel therapeutic targets for nephrotic syndrome. Clin Exp Nephrol 2009; 13: 275-280.
4. Sugimoto H, Hamano Y, Charytan D et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003; 278: 12605-12608.
5. Eremina V, Sood M, Haigh J et al. Glomerular-specific alterations of VEGFA expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707-716.
6. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129-1136.
7. Ganju RK, Munshi N, Nair BC et al. Human immunodeficiency virus tat modulates the Flk-1/KDR receptor, mitogen-activated protein kinases, and components of focal adhesion in Kaposi's sarcoma cells. J Virol 1998; 72: 6131-6137.
8. Maynard SE, Min JY, Merchan J et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658.
9. Masuda Y, Shimizu A, Mori T et al. Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol 2001; 159: 599-608.
10. Kim YG, Suga SI, Kang DH et al. Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kidney Int 2000; 58: 2390-2399.
11. Izzedine H, Massard C, Spano JP et al. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 2010; 46: 439-448.
12. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Eng J Med 2003; 349: 427-434.
13. Hemmelgarn BR, Manns BJ, Lloyd A et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010; 303: 423-429.
14. Matsushita K, van der Velde M, Astor BC et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-2081.
15. Zhu X, Wu S, Dahut WL et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49: 186-193.
16. Wu S, Kim C, Baer L et al. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 2010; 21: 1381-1389.
17. Jhaveri KD, Flombaum CD, Kroog G et al. Nephrotoxicities associated with the use of tyrosine kinase inhibitors: a single-center experience and review of the literature. Nephron Clin Pract 2010; 117: c312-c319.
18. Bollée G, Patey N, Cazajous G et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant 2009; 24: 682-685.
19. Patel TV, Morgan JA, Demetri GD et al. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 2008; 100: 282-284.
20. Hurwitz HI, Dowlati A, Saini S et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009; 15: 4220-4227.
21. Hutson TE, Davis ID, Machiels JP et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010; 28: 475-480.
22. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-1068.
23. Robinson ES, Matulonis UA, Ivy P et al. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin J Am Soc Nephrol 2010; 5: 477-483.
24. Ranpura V, Pulipati B, Chu D et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010; 23: 460-468.
25. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and metaanalysis. Acta Oncologica 2009; 48: 9-17.
26. Veronese ML, Mosenkis A, Flaherty KT et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006; 24: 1363-1369.
27. Hood JD, Meininger CJ, Ziche M et al. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998; 274: 1054-1058.
28. Henry TD, Annex BH, McKendall GR et al. The VIVA trial: vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 2003; 107: 1359-1365.
29. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-2191.
30. George BA, Zhou XJ, Toto R. Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis 2007; 49: e23-e29.
31. Barakat RK, Singh N, Lal R et al. Interstitial nephritis secondary to bevacizumab treatment in metastatic leiomyosarcoma. Ann Pharmacother 2007; 41: 707-710.
32. Izzedine H, Brocheriou I, Rixe O et al. Interstitial nephritis in a patient taking sorafenib. Nephrol Dial Transplant 2007; 22: 2411.
33. Stylianou K, Lioudaki E, Papadimitraki E et al. Crescentic glomerulonephritis associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration. Nephrol Dial Transplant 2011; 26: 1742-1745.
34. Cancer Therapy Evaluation Programme. Common Terminology Criteria for Adverse Events (version 3.0; March 31, 2003). National Cancer Institute, National Institutes of Health: Rockville, MD. http://ctep.cancer.gov/ protocoldevelopment/electronic-applications/docs/ctcaev3.pdf(accessed 22 March 2010).